Physician profile
Stephen John Chalmers
NPI 1134166143
$3,005.41
in general payments reported to CMS, 2019-2025
27 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $173 · 2021: $206 · 2022: $449 · 2023: $560 · 2024: $684 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $656.35 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $461.58 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $378.12 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $204.97 | 2019-2024 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $152.98 | 2022-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $142.81 | 2021-2024 | Acthar |
| Nxstage Medical, INC. | $139.76 | 2019 | |
| Calliditas Therapeutics US INC. | $133.06 | 2023-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $119.87 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.79 | 2024-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $60.12 | 2019 | |
| Travere Therapeutics, INC. | $59.42 | 2023 | |
| Akebia Therapeutics INC | $51.86 | 2025 | Vafseo |
| Aurinia Pharma U.S., INC. | $51.61 | 2022 | |
| Ardelyx, INC. | $45.71 | 2024-2025 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $44.43 | 2020-2022 | |
| Glaxosmithkline, LLC. | $35.45 | 2021-2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $33.81 | 2025 | Ozempic, Wegovy |
| Scpharmaceuticals INC. | $26.97 | 2025 | |
| Alnylam Pharmaceuticals INC. | $24.55 | 2023 | Onpattro |
| Apellis Pharmaceuticals, INC. | $21.02 | 2025 | Empaveli |
| Kyowa Kirin, INC. | $18.23 | 2025 | |
| Amicus Therapeutics, INC. | $17.67 | 2023 | Galafold |
| Takeda Pharmaceuticals U.S.A., INC. | $17.17 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.69 | 2020 | |
| Bard Peripheral Vascular, INC. | $13.96 | 2020 | |
| Genentech USA, INC. | $13.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Chalmers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.